Sanofi

IPG Tops the 2024 Ad Age 'A-List'

Retrieved on: 
Monday, March 11, 2024

New York, NY, March 11, 2024 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG) today announced that five of its agencies were honored at the Ad Age A-List & Creativity Awards — the trade publication's coveted ranking of agencies, companies and innovators and their efforts to move the advertising industry forward, with IPG companies winning more honors than any other agency group. Recognized as top-performers in the industry, IPG Health, IPG Mediabrands, The Martin Agency, UM and The Weber Shandwick Collective were honored for their innovative and market-moving work across the advertising, media, PR and healthcare sectors.

Key Points: 
  • Recognized as top-performers in the industry, IPG Health, IPG Mediabrands, The Martin Agency, UM and The Weber Shandwick Collective were honored for their innovative and market-moving work across the advertising, media, PR and healthcare sectors.
  • 5 position on Ad Age’s 2024 Agency A-List, marking its second consecutive year on the esteemed list.
  • Since the introduction of this category last year, IPG Health remains the sole healthcare network to receive this prestigious accolade.
  • Additionally, under the leadership of Eileen Kiernan, IPG Mediabrands stood out as Ad Age's 2024 U.S. Network of the Year.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Retrieved on: 
Wednesday, February 28, 2024

CHATHAM, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy volunteers. TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.

Key Points: 
  • TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.
  • “Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Anti-CD40L modulates T cell function and has the potential to promote tolerance of transplanted organs.
  • We are excited to have completed the clinical stage of this Phase 1 trial of TNX-1500, a third-generation Fc-modified anti-CD40L mAb that has been designed by protein engineering to eliminate the risk of thrombosis associated with first-generation anti-CD40L mAbs.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, February 26, 2024

“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.

Key Points: 
  • “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
  • Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
  • Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Retrieved on: 
Friday, February 23, 2024

Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Key Points: 
  • Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
    Paris, February 23, 2024.
  • Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
  • These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-r...
    In addition, the Form 20-F is available on the website of the SEC ( www.sec.gov ) and the “Document d’Enregistrement Universel” is available on the website of the AMF ( www.amf-france.org ).
  • A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.

Crisp Raises $50M in Series B Extension as CPG Brands Rapidly Adopt a Collaborative Commerce Approach for Sales, Marketing and Supply Chain Management

Retrieved on: 
Thursday, February 22, 2024

TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.

Key Points: 
  • TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.
  • Crisp previously raised a total of $60M in equity, bringing the total equity raised to $80M.
  • These insights enable brands and retailers to optimize the manufacturing, distribution, merchandising and marketing of CPG products through every retail channel.
  • We solve real problems and help CPG brands strengthen sales, marketing, and their relationships with retailers,” said Are Traasdahl, founder and CEO of Crisp.

ORI Capital Raises $260 Million for Second Life Sciences Fund

Retrieved on: 
Thursday, February 22, 2024

ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.

Key Points: 
  • ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.
  • Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies.
  • ORI Capital is a pioneer in adopting a quantamental strategy in biotech venture investment combing data analysis with fundamental research.
  • ORI Healthcare Fund II will actively deploy capital in these new approaches to support truly innovative companies that can bring hope to patients in need globally.